Chloroquine

also known as Chloroquine phosphate · Chloroquine Diphosphate · Chloroquine Sulfate · A-CQ 100 · Aralen · Aralen GENERIC NAME(S): Chloroquine Phosphate · Chloroquine phosphate GPO · Chloroquine sulphate · +3 more

Small molecule targets ATM, TNF via activation / inhibition

Developed for: Plasmodium falciparum malaria · malaria · Plasmodium vivax malaria · COVID-19 · HIV infectious disease · anemia · glioblastoma · metastatic malignant neoplasm in the brain
+33 more
· astrocytoma (excluding glioblastoma) · atopic eczema · atrial fibrillation · cancer · chikungunya · chondrosarcoma · chronic hepatitis C virus infection · ductal breast carcinoma in situ · glioma · gliosarcoma · influenza · intrahepatic cholangiocarcinoma · invasive breast carcinoma · lung disorder · malignant pancreatic neoplasm · metabolic syndrome X · neoplasm · osteoarthritis, knee · pancreatic adenocarcinoma · parasitemia · plasma cell myeloma · pneumonia · prolactin-producing pituitary gland adenoma · psoriasis · small cell lung carcinoma · tuberculosis · viral pneumonia · autoimmune hepatitis · chronic congestive splenomegaly · dengue disease · severe acute respiratory syndrome · sexually transmitted disease · sickle cell disease
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · London School of Hygiene and Tropical Medicine · Pfizer · Centers for Disease Control and Prevention · University of Oxford · Menzies School of Health Research
+149 more
· Bandim Health Project · Columbia University · DBL -Institute for Health Research and Development · Kamuzu University of Health Sciences · Maastricht Radiation Oncology · University of Maryland, Baltimore · Doris Duke Charitable Foundation · GlaxoSmithKline · HealthNet TPO · Institute of Tropical Medicine, Belgium · Mahidol Oxford Tropical Medicine Research Unit · Mahidol University · Medicines for Malaria Venture · Oswaldo Cruz Foundation · PATH · Pan American Health Organization · Tanta University · United States Agency for International Development (USAID) · University of California, San Francisco · University of Zurich · World Health Organization · AHEPA University Hospital · Academic Medical Center - University of Amsterdam · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Agenus Inc. · Ardabil University of Medical Sciences · Armauer Hansen Research Institute, Ethiopia · Asan Medical Center · Assistance Publique Hopitaux De Marseille · Athens General Hospital Hippokrateio · Barbara Ann Karmanos Cancer Institute · Beijing Chao Yang Hospital · Beijing Tiantan Hospital · CIHR Canadian HIV Trials Network · CMN "20 de Noviembre" · Can Gio COVID Hospital, Vietnam · Caring Friends, Mumbai · Cayenne Hospital · Centre Muraz · Centro Nacional de Vigilancia Epidemiológica y control de enfermedades (CENAVECE), Mexico · Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva · Chinese PLA General Hospital · Cho Ray Hospital · Corfu General Hospital Agia Irini · Cu Chi COVID Hospital, Vietnam · Department of Health, Ho Chi Minh city · Department of Health, Philippines · Departments of Parasitology and Public Health, ITM, Antwerp, Belgium · Dinka Dugassa · Divine Providence Hospital Pammakaristos · Dr. Frank Arguello Cancer Clinic · Egyptian Medical Syndicate · Ethiopian Health and Nutrition Research Institute · Ethiopian Public Health Institute · Federal Minstry of Health of Ethiopia · First Affiliated Hospital of Fujian Medical University · First Affiliated Hospital of Wenzhou Medical University · First Hospital of China Medical University · Foundation for Scientific Research Suriname (SWOS) Paramaribo, Suriname · Fundacion Clinica Valle del Lili · George Mason University · HaEmek Medical Center, Israel · HonorHealth Research Institute · Hospital Hietzing · Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam · Huashan Hospital · Inova Health Care Services · Institut Pasteur · Institut Pasteur de Madagascar · Institut Pasteur, Cambodia · Institute for Epidemiology and Social Medicine, Aarhus University, Denmark · Instituto Nacional de Laboratorios de Salud (INLASA) · Instituto de Ciencia y Medicina Genomica, Torreon, Coah. Mexico www.institutodeciencia.com · Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), Mexico · all 155 on the full record

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	ARALEN	—	1949-10-31	fda.gov ↗

Trials 103 · started per year

today

US approved 1949

1948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 115 trials · 1 missed
Phase 1	NCT06076837	Jan → Dec 2025	pancreatic adenocarcinoma	HonorHealth Research Institute	Terminated	No outcome recorded
Phase 1	NCT05443178	Jan 2022 → Oct 2024	tuberculosis	University of Zurich	Unknown	No outcome recorded
Phase 1	NCT04397679	Aug 2021 → May 2024	gliosarcoma	Barbara Ann Karmanos Cancer Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT04443270	Jul → Oct 2020	COVID-19	CMN "20 de Noviembre"	Unknown	No outcome recorded
Phase 1	NCT03083847	Jun 2017 → Jun 2019	malaria	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT02378532	Aug 2016 → Jan 2019	glioblastoma	Maastricht Radiation Oncology	Completed	Missed primary
Phase 1	NCT02511054	Jul 2015 → Oct 2016	malaria	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT02071537	May 2014 → Mar 2018	cancer	University of Cincinnati	Completed	No outcome recorded
Phase 1	NCT01575782	May 2014 → Jul 2017	small cell lung carcinoma	Maastricht Radiation Oncology	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT01777477	Jul 2012 → May 2015	malignant pancreatic neoplasm	University of Zurich	Completed	No outcome recorded
Phase 1	NCT01546389	Apr 2012 → Apr 2013	malaria	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT01500980	Dec 2011 → Jul 2012	Plasmodium falciparum malaria	Seattle Children's Hospital	Completed	No outcome recorded
Phase 1	NCT01366235	May → Oct 2011	—	Asan Medical Center	Completed	No outcome recorded
Phase 1	NCT01218932	Oct 2010 → Oct 2011	Plasmodium vivax malaria	University of Oxford	Completed	No outcome recorded
Phase 1	NCT01100060	Apr → Jun 2010	—	Pfizer	Completed	No outcome recorded

Phase 1/24 trials
Phase 1/2	NCT03952650	May 2019 → Feb 2021	malaria	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT04772846	Mar 2018 → Dec 2020	glioblastoma	Egyptian Medical Syndicate	Unknown	No outcome recorded
Phase 1/2	NCT02496741	Nov 2015 → Nov 2019	chondrosarcoma, glioma, intrahepatic cholangiocarcinoma	Academic Medical Center - University of Amsterdam	Completed	No outcome recorded
Phase 1/2	NCT01023477	Dec 2009 → Oct 2016	ductal breast carcinoma in situ	Inova Health Care Services	Completed	No outcome recorded
Phase 217 trials · 2 missed
Phase 2	NCT02432417	Nov 2023	astrocytoma (excluding glioblastoma), glioblastoma	Maastricht Radiation Oncology	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT04349371	Apr 2020 → Feb 2021	COVID-19	Columbia University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT04328493	Apr → Sep 2020	COVID-19	Oxford University Clinical Research Unit, Vietnam	Completed	No outcome recorded
Phase 2	NCT04344951	Apr → Nov 2020	COVID-19, viral pneumonia	Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.	Terminated	No outcome recorded
Phase 2	NCT04627467	Mar → Jul 2020	COVID-19	Fundacion Clinica Valle del Lili	Completed	No outcome recorded
Phase 2	NCT02932007	Mar 2017 → Mar 2020 overdue	atrial fibrillation	University of South Florida	Recruiting	No outcome recorded
Phase 2	NCT02333890	Jul 2015 → Mar 2017	invasive breast carcinoma	Ottawa Hospital Research Institute	Unknown	No outcome recorded
Phase 2	NCT01438177	Oct 2011 → Feb 2014	plasma cell myeloma	NYU Langone Health	Terminated	No outcome recorded
Phase 2	NCT02366884	Jul 2011 → Dec 2022	neoplasm	Dr. Frank Arguello Cancer Clinic	Unknown	No outcome recorded
Phase 2	NCT01894633	May 2011 → Apr 2012	metastatic malignant neoplasm in the brain	National Cancer Institute of Mexico	Terminated	No outcome recorded
Phase 2	NCT00972725	Dec 2009 → Oct 2010	AIDS	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01078779	Nov 2009 → May 2010	influenza	National University Hospital, Singapore	Unknown	Missed primary
Phase 2	NCT00819390	Mar 2009 → Feb 2013	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	Missed primary
Phase 2	NCT00282919	Mar 2006 → Feb 2008	Plasmodium falciparum malaria	Pfizer	Completed	No outcome recorded
Phase 2	NCT00082563	Aug → Nov 2004	Plasmodium falciparum malaria	Pfizer	Terminated	No outcome recorded
Phase 2	NCT00486694	Mar → Aug 2004	Plasmodium vivax malaria	London School of Hygiene and Tropical Medicine	Completed	No outcome recorded
Phase 2	NCT00959517	Jul 2001 → Jun 2005	Plasmodium falciparum malaria	London School of Hygiene and Tropical Medicine	Completed	No outcome recorded

Phase 2/310 trials · 3 met primary · 1 missed
Phase 2/3	NCT04333628	Jun → Sep 2020	COVID-19	HaEmek Medical Center, Israel	Terminated	No outcome recorded
Phase 2/3	NCT04351724	Apr 2020 → Dec 2021	COVID-19	Medical University of Vienna	Unknown	Met primary
Phase 2/3	NCT04353336	Mar → Jun 2020	COVID-19	Tanta University	Completed	No outcome recorded
Phase 2/3	NCT04319900	Mar → Apr 2020	COVID-19	Beijing Chao Yang Hospital	Unknown	No outcome recorded
Phase 2/3	NCT02698748	Jan → Apr 2015	malaria	Manhiça Health Research Centre	Completed	Met primary
Phase 2/3	NCT02691910	Aug 2014 → Aug 2015	Plasmodium vivax malaria	Oswaldo Cruz Foundation	Completed	No outcome recorded
Phase 2/3	NCT00677833	Jun 2008 → Sep 2010	Plasmodium falciparum malaria	Pfizer	Completed	Missed primary
Phase 2/3	NCT00308620	Mar 2006 → Dec 2008	HIV infectious disease	University of Minnesota	Terminated	No outcome recorded Stop: Business
Phase 2/3	NCT00084227	Jul 2004 → Jul 2005	Plasmodium falciparum malaria	Pfizer	Completed	No outcome recorded
Phase 2/3	NCT00082576	Jun 2004 → May 2006	Plasmodium falciparum malaria	Pfizer	Completed	Met primary
Phase 317 trials · 2 met primary · 5 missed
Phase 3	NCT06923592	May 2025 → Apr 2027 expected	Plasmodium falciparum malaria, Plasmodium vivax malaria	London School of Hygiene and Tropical Medicine	Recruiting	No outcome recorded
Phase 3	NCT05690841	Oct 2024 → May 2027 expected	Plasmodium vivax malaria	University of California, San Francisco	Recruiting	No outcome recorded
Phase 3	NCT04447534	Jun → Jul 2020	COVID-19	Tanta University	Completed	Missed primary
Phase 3	NCT04360759	May 2020 → May 2021	COVID-19, HIV infectious disease	University of Cape Town	Withdrawn	No outcome recorded
Phase 3	NCT04420247	Apr → Aug 2020	COVID-19	Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva	Completed	Missed primary
Phase 3	NCT01443130	Feb 2012 → Oct 2014	malaria	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT01103713	Mar 2011 → Jun 2013	parasitemia	Pfizer	Terminated	No outcome recorded
Phase 3	NCT01103063	Oct 2010 → Oct 2013	—	Pfizer	Terminated	Missed primary
Phase 3	NCT01074905	May 2010 → Oct 2012	Plasmodium vivax malaria	University of Oxford	Completed	No outcome recorded
Phase 3	NCT00379821	Feb 2007 → Aug 2009	Plasmodium falciparum malaria	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00367653	Nov 2006 → Sep 2007	Plasmodium falciparum malaria	Pfizer	Completed	Met primary
Phase 3	NCT00391313	May 2006 → Mar 2007	chikungunya	Assistance Publique Hopitaux De Marseille	Terminated	No outcome recorded
Phase 3	NCT00224978	Jan → Aug 2005	glioblastoma	National Institute of Neurology and Neurosurgery, Mexico	Completed	Missed primary
Phase 3	NCT00118807	Aug 2003 → Feb 2004	Plasmodium falciparum malaria	London School of Hygiene and Tropical Medicine	Completed	No outcome recorded
Phase 3	NCT00131703	Mar 2003 → Mar 2005	malaria, pregnancy disorder	London School of Hygiene and Tropical Medicine	Completed	Met primary
Phase 3	NCT00442403	Apr → Sep 2002	Plasmodium falciparum malaria	Université Victor Segalen Bordeaux 2	Suspended	No outcome recorded
Phase 3	NCT00158548	Jun 2001 → Dec 2004	Plasmodium falciparum malaria, Plasmodium vivax malaria	London School of Hygiene and Tropical Medicine	Completed	No outcome recorded

Phase 423 trials · 1 met primary
Phase 4	NCT07352566	Aug 2026 → Jun 2030 expected	atopic eczema, psoriasis	University of California, San Francisco	Not yet recruiting	No outcome recorded
Phase 4	NCT06083688	Oct 2024 → Jul 2025 overdue	Plasmodium falciparum malaria, anemia	Liverpool School of Tropical Medicine	Active not recruiting	No outcome recorded
Phase 4	NCT05788094	Jun 2023 → Feb 2026 overdue	Plasmodium vivax malaria	Shoklo Malaria Research Unit	Recruiting	No outcome recorded
Phase 4	NCT05980156	Feb → Jul 2023	Plasmodium falciparum malaria, anemia	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 4	NCT06044805	Dec 2022 → Mar 2023	Plasmodium vivax malaria	Dinka Dugassa	Completed	No outcome recorded
Phase 4	NCT05244954	Feb → Aug 2022	Plasmodium falciparum malaria, anemia	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 4	NCT04331600	Apr → Dec 2020	COVID-19	Wroclaw Medical University	Completed	No outcome recorded
Phase 4	NCT03337152	May → Aug 2018	G6PD deficiency, Plasmodium vivax malaria	PATH	Terminated	No outcome recorded
Phase 4	NCT02564471	Nov 2016 → Aug 2018	rabies	State University of New York - Upstate Medical University	Completed	No outcome recorded
Phase 4	NCT02610686	Mar 2015 → Oct 2016	Plasmodium vivax malaria	National Institute of Malariology, Parasitology and Entomology, Vietnam	Unknown	No outcome recorded
Phase 4	NCT02389374	Aug 2014 → Mar 2015	malaria	Menzies School of Health Research	Completed	No outcome recorded
Phase 4	NCT02118090	May → Dec 2014	Plasmodium vivax malaria	Institut Pasteur, Cambodia	Completed	No outcome recorded
Phase 4	NCT02058173	Jan → Jun 2014	chronic hepatitis C virus infection	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT01814423	Apr 2013 → Feb 2014	malaria	Bandim Health Project	Completed	No outcome recorded
Phase 4	NCT01680406	Oct 2012 → Dec 2014	Plasmodium vivax malaria	Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 4	NCT00805519	Feb 2009 → Apr 2010	osteoarthritis, knee	Ardabil University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT02394197	Feb 2008 → Sep 2010	Plasmodium vivax malaria	LILIA GONZALEZ CERON	Completed	No outcome recorded
Phase 4	NCT00426439	Dec 2006 → Nov 2008	Plasmodium falciparum malaria	Bandim Health Project	Completed	No outcome recorded
Phase 4	NCT00290420	Mar 2006 → Nov 2007	Plasmodium vivax malaria	Research Institute for Development	Withdrawn	No outcome recorded
Phase 4	NCT00125489	May → Dec 2005	Plasmodium falciparum malaria	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 4	NCT07436104	Jan 2004 → Dec 2015	asthma, chronic diarrheal disease, chronic obstructive pulmonary disease, hypertensive disorder +2	MAHAN Trust	Completed	No outcome recorded
Phase 4	NCT00680732	Jun 2003 → Oct 2006	malaria	Institute of Tropical Medicine, Belgium	Completed	No outcome recorded
Phase 4	NCT00137514	Mar 2001 → May 2004	Plasmodium falciparum malaria	Bandim Health Project	Completed	No outcome recorded

Phase not applicable17 trials · 2 missed
—	NCT05540470	Sep 2022 → Mar 2025	Plasmodium vivax malaria	Cayenne Hospital	Completed	No outcome recorded
—	NCT04303507	Apr 2020 → Mar 2022	COVID-19, lung disorder	University of Oxford	Completed	Missed primary
—	NCT03400865	Oct 2018 → Dec 2020	prolactin-producing pituitary gland adenoma	Zhebao Wu	Unknown	No outcome recorded
—	NCT02043652	Feb → Dec 2014	malaria	Centers for Disease Control and Prevention	Completed	No outcome recorded
—	NCT01650558	Nov 2012 → Jul 2018	HIV infectious disease	University of Maryland, Baltimore	Completed	No outcome recorded
—	NCT01546961	Jun 2011 → Nov 2016	Plasmodium vivax malaria	University of Oxford	Completed	No outcome recorded
—	NCT02004314	Oct 2009 → Jan 2012	HIV infectious disease	CIHR Canadian HIV Trials Network	Completed	No outcome recorded
—	NCT01052584	Oct 2009 → Jan 2010	malaria	Centers for Disease Control and Prevention	Completed	No outcome recorded
—	NCT01727531	Dec 2008 → Aug 2013	metastatic malignant neoplasm in the brain	Main Line Health	Completed	No outcome recorded
—	NCT00455403	Apr 2006 → Dec 2009	hyperlipidemia, hypertensive disorder, metabolic syndrome X, obesity disorder +1	Washington University School of Medicine	Completed	Missed primary
—	NCT00259142	Nov 2005	anemia, malaria	DBL -Institute for Health Research and Development	Terminated	No outcome recorded
—	NCT00127998	Jul 2005 → ?	malaria	Centers for Disease Control and Prevention	Completed	No outcome recorded
—	NCT00157859	Apr → Sep 2004	Plasmodium falciparum malaria, Plasmodium vivax malaria	Menzies School of Health Research	Completed	No outcome recorded
—	NCT00132535	Aug 2003 → Jun 2007	HIV infectious disease, malaria	London School of Hygiene and Tropical Medicine	Completed	No outcome recorded
—	NCT00229775	Jul 2003 → Jul 2008	malaria	Centers for Disease Control and Prevention	Completed	No outcome recorded
—	NCT00140517	Oct 2002 → Jun 2007	Plasmodium falciparum malaria, anemia	London School of Hygiene and Tropical Medicine	Completed	No outcome recorded
—	NCT00169078	Jul → Dec 2002	malaria	London School of Hygiene and Tropical Medicine	Completed	No outcome recorded

Comparator or background therapy77 trials
Phase 1	NCT02996695 Background	Apr 2017 → Jun 2018	Plasmodium falciparum malaria	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT03070470 Comparator	Mar → Jun 2017	—	Food and Drug Administration (FDA)	Completed	No outcome recorded
Phase 1	NCT02773979 Comparator	Sep 2016 → Jan 2018	Plasmodium falciparum malaria	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00969306 Comparator	Sep 2013 → Jun 2016	small cell lung carcinoma	Maastricht Radiation Oncology	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT01205178 Comparator	Jul 2009 → Apr 2013	malaria	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00871156 Comparator	Mar → Aug 2009	malaria	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00844207 Comparator	Feb → Apr 2009	malaria	Pfizer	Completed	No outcome recorded
Phase 1	NCT00323375 Comparator	Aug 1999 → Jun 2005	malaria	Tulane University Health Sciences Center	Completed	No outcome recorded
Phase 1/2	NCT00849602 Comparator	Feb → May 2008	dengue disease	University of Sao Paulo	Unknown	No outcome recorded
Phase 2	NCT07835321 Background	Sep 2026 → Dec 2029 expected	Plasmodium vivax malaria	University of Oxford	Not yet recruiting	No outcome recorded
Phase 2	NCT07430592 Comparator	Jul 2026 → Nov 2028 expected	Plasmodium vivax malaria	R. Kiplin Guy	Not yet recruiting	No outcome recorded
Phase 2	NCT03503058 Comparator	May 2022 → Feb 2024	malaria	Sanaria Inc.	Completed	No outcome recorded
Phase 2	NCT04342650 Comparator	Apr → May 2020	COVID-19, severe acute respiratory syndrome	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	Completed	No outcome recorded
Phase 2	NCT04428268 Background	Mar → Jun 2020	pneumonia	Hospital Universitario Dr. Jose E. Gonzalez	Withdrawn	No outcome recorded
Phase 2	NCT03278808 Comparator	Sep 2018 → Dec 2019	malaria	U.S. Army Medical Research and Development Command	Withdrawn	No outcome recorded
Phase 2	NCT03529396 Comparator	Jul 2018 → Dec 2022	G6PD deficiency, Plasmodium vivax malaria	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	Completed	No outcome recorded
Phase 2	NCT02563496 Background	Feb 2017 → Dec 2019	Plasmodium vivax malaria	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01376167 Background	Apr 2014 → Nov 2016	Plasmodium vivax malaria	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT01946880 Background	Nov 2013 → Jul 2019	systemic lupus erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	Met primary Stop: Enrollment
Phase 2	NCT00811096 Comparator	Nov 2008 → Jan 2009	Plasmodium vivax malaria	Walter Reed Army Institute of Research (WRAIR)	Completed	Missed primary
Phase 2	NCT00455325 Comparator	Sep 2004 → Jun 2010	hyperlipidemia, hypertensive disorder, metabolic syndrome X, obesity disorder +1	Washington University School of Medicine	Completed	No outcome recorded
Phase 2	NCT01290601 Comparator	Sep 2003 → Jan 2005	Plasmodium vivax malaria	U.S. Army Medical Research and Development Command	Terminated	No outcome recorded
Phase 2/3	NCT05232227 Background	Jan → Jun 2023	Plasmodium vivax malaria	University of California, San Francisco	Withdrawn	No outcome recorded Stop: Business
Phase 2/3	NCT04395170 Background	Sep → Dec 2020	COVID-19	Lifefactors Zona Franca, SAS	Unknown	No outcome recorded
Phase 2/3	NCT04434248 Comparator	Apr → Jul 2020	COVID-19	Chromis LLC	Unknown	No outcome recorded
Phase 2/3	NCT04351295 Comparator	Apr → Sep 2020	COVID-19	Tanta University	Completed	No outcome recorded
Phase 2/3	NCT04475120 Comparator	Apr → Jul 2020	COVID-19	University of Rome Tor Vergata	Completed	No outcome recorded
Phase 2/3	NCT01718054 Comparator	Aug 2012 → Sep 2016	sickle cell disease	London School of Hygiene and Tropical Medicine	Unknown	No outcome recorded
Phase 2/3	NCT00084240 Background	Mar 2004 → Apr 2005	Plasmodium falciparum malaria	Pfizer	Terminated	No outcome recorded
Phase 2/3	NCT00074841 Background	Sep 2003 → Jan 2005	Plasmodium falciparum malaria	Pfizer	Completed	No outcome recorded
Phase 3	NCT06666491 Background	Nov 2024 → May 2027 expected	Plasmodium vivax malaria	GlaxoSmithKline	Recruiting	No outcome recorded
Phase 3	NCT04501783 Comparator	May → Jul 2020	COVID-19	R-Pharm	Completed	No outcome recorded
Phase 3	NCT04341727 Comparator	Apr 2020 → Apr 2021	COVID-19	Washington University School of Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT03208907 Comparator	Jul 2018 → Jul 2021	Plasmodium vivax malaria	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	Completed	No outcome recorded
Phase 3	NCT02873936 Background	Jul 2016 → Mar 2018	rheumatoid arthritis	Gilead Sciences	Completed	Met primary
Phase 3	NCT01785979 Comparator	Jan 2016 → Feb 2017	anemia, chronic congestive splenomegaly, malaria	Lihir Medical Centre	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT02216123 Background	Apr 2015 → Nov 2016	Plasmodium vivax malaria	GlaxoSmithKline	Completed	Missed primary
Phase 3	NCT02348788 Comparator	Jan 2015 → Dec 2017	Plasmodium vivax malaria	Menzies School of Health Research	Unknown	No outcome recorded
Phase 3	NCT02001012 Comparator	Jan 2014 → Jan 2015	—	Menzies School of Health Research	Completed	No outcome recorded
Phase 3	NCT01941095 Background	Nov 2013 → Jul 2016	rheumatoid arthritis	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT01708876 Comparator	Oct 2012 → Dec 2014	—	Menzies School of Health Research	Completed	No outcome recorded
Phase 3	NCT01640574 Comparator	Feb 2012 → Jul 2015	Plasmodium vivax malaria	University of Oxford	Completed	No outcome recorded
Phase 3	NCT01378286 Comparator	Jan 2012 → Jun 2013	malaria	Sanofi	Completed	Met primary
Phase 3	NCT01256736 Background	Mar 2010 → Dec 2011	rheumatoid arthritis	JW Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT01136850 Comparator	Nov 2009 → Dec 2012	anemia, malaria, sexually transmitted disease	University of Melbourne	Completed	Met primary
Phase 3	NCT01211834 Comparator	Oct 2009 → Oct 2010	rheumatoid arthritis	JW Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT00531817 Background	Oct 2007 → Jun 2009	rheumatoid arthritis	Hoffmann-La Roche	Completed	Met primary
Phase 3	NCT04368910 Comparator	Sep 2007 → Oct 2010	malaria	Medicines for Malaria Venture	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00682578 Comparator	Jul 2007 → Feb 2010	Plasmodium falciparum malaria, Plasmodium vivax malaria	University of Oxford	Completed	Met primary
Phase 3	NCT00521924 Comparator	Jun 2007 → Apr 2008	rheumatoid arthritis	Merck Sharp & Dohme LLC	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00440999 Comparator	Mar 2007 → Apr 2008	Plasmodium vivax malaria	Medicines for Malaria Venture	Completed	Met primary
Phase 3	NCT00720798 Background	Sep 2005 → Apr 2013	rheumatoid arthritis	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00730366 Comparator	Mar 2004 → Oct 2006	Plasmodium falciparum malaria	Institute of Tropical Medicine, Belgium	Completed	No outcome recorded
Phase 4	NCT04704999 Comparator	Jul 2024 → Oct 2027 expected	Plasmodium vivax malaria	University of Oxford	Recruiting	No outcome recorded
Phase 4	NCT04351191 Comparator	Apr → Aug 2020	COVID-19	Government of Punjab, Specialized Healthcare and Medical Education Department	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT04362332 Comparator	Apr → Jun 2020	COVID-19	UMC Utrecht	Terminated	No outcome recorded
Phase 4	NCT04346667 Comparator	Apr → Aug 2020	COVID-19	Government of Punjab, Specialized Healthcare and Medical Education Department	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT04286503 Comparator	Feb 2020 → Feb 2021	COVID-19	Beijing YouAn Hospital	Unknown	No outcome recorded
Phase 4	NCT03449758 Background	Mar 2018 → Jul 2019	rheumatoid arthritis	Sanofi	Completed	No outcome recorded
Phase 4	NCT02876549 Background	Sep 2016 → Nov 2018	Plasmodium vivax malaria	University of Oxford	Completed	No outcome recorded
Phase 4	NCT02192944 Comparator	Jul 2014 → Sep 2015	—	University of Oxford	Completed	No outcome recorded
Phase 4	NCT01887821 Comparator	Feb 2013 → Jun 2015	Plasmodium vivax malaria	Oxford University Clinical Research Unit, Vietnam	Completed	No outcome recorded
Phase 4	NCT01662700 Comparator	Oct 2012 → Dec 2014	Plasmodium vivax malaria	Mahidol University	Unknown	No outcome recorded
Phase 4	NCT01107145 Comparator	Feb 2011 → Jan 2012	Plasmodium vivax malaria	Centers for Disease Control and Prevention	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00964691 Comparator	Aug 2009 → Aug 2010	malaria	Ministry of Health and Medical Services, Solomon Islands	Terminated	No outcome recorded
Phase 4	NCT01178021 Comparator	Aug 2009 → Feb 2014	Plasmodium vivax malaria	University of Oxford	Completed	No outcome recorded
Phase 4	NCT02143934 Comparator	Aug 2009 → May 2010	Plasmodium falciparum malaria, Plasmodium vivax malaria	Papua New Guinea Institute of Medical Research	Completed	No outcome recorded
Phase 4	NCT02463331 Comparator	May 2003 → Jun 2015	autoimmune hepatitis	University of Sao Paulo General Hospital	Completed	Missed primary
Phase 4	NCT01980745 Comparator	Feb 2002 → Nov 2013	autoimmune hepatitis	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 4	NCT01019408 Comparator	Nov 1993 → Jan 1995	Plasmodium falciparum malaria	London School of Hygiene and Tropical Medicine	Completed	No outcome recorded
—	NCT07533136 Comparator	May 2026 → Oct 2028 expected	Plasmodium vivax malaria	Walter Reed Army Institute of Research (WRAIR)	Not yet recruiting	No outcome recorded
—	NCT02098590 Background	Oct 2014 → Nov 2015	malaria	Radboud University Medical Center	Completed	No outcome recorded
—	NCT02080026 Background	Jun 2014 → Jul 2015	malaria	Radboud University Medical Center	Completed	No outcome recorded
—	NCT01422954 Comparator	Jan → Dec 2012	Plasmodium falciparum malaria	Radboud University Medical Center	Completed	No outcome recorded
—	NCT01236612 Background	Apr 2011 → Jun 2012	Plasmodium falciparum malaria	Radboud University Medical Center	Completed	No outcome recorded
—	NCT01218893 Background	Apr 2011 → Jan 2012	Plasmodium falciparum malaria	Radboud University Medical Center	Completed	No outcome recorded
—	NCT00473837 Comparator	Jul 2007 → Feb 2009	malaria	Medical Research Council Unit, The Gambia	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 2

Date	Issuer	Release
2021-06-30	Sanaria Inc.	Results SANARIA VACCINE TRIAL RESULTS DEMONSTRATE UNPRECEDENTED PROGRESS IN WORLDWIDE BATTLE AGAINST VARIANT MALARIA PARASITES sanaria.com ↗ This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration.
2003-11-02	Impax Laboratories, LLC	Regulatory IMPAX Receives FDA Approval for Generic Aralen amneal.com ↗ HAYWARD, Calif.--(BUSINESS WIRE)--Sept. 2, 2003--IMPAX Laboratories, Inc. (NASDAQ: IPXL - News) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to the Company's Abbreviated New Drug Application (ANDA) for a generic version of Aralen® (Chloroquine Phosphate) 500 mg tablets.

All press releases naming this drug 2 releases

Date	Issuer	Release
2021-06-30	Sanaria Inc.	SANARIA VACCINE TRIAL RESULTS DEMONSTRATE UNPRECEDENTED PROGRESS IN WORLDWIDE BATTLE AGAINST VARIANT MALARIA PARASITES sanaria.com ↗
2003-11-02	Impax Laboratories, LLC	IMPAX Receives FDA Approval for Generic Aralen amneal.com ↗

Evidence & citations 16 cited values

Every value below carries the sentence it was read from. 181 sources stand behind the page.

Field	Value	Cited text
Known as	Chloroquine	“If the enzyme activity is normal and no other contra-indication for treatment are found, the participants will be treated with 14 days of primaquine 0.25mg/kg/day OR 7 days of...” NCT06923592 ↗ 176 “The fMDA regimen will include 25mg/kg chloroquine (CQ) plus a single 300mg dose of tafenoquine (TQ) for individuals age ≥16 years, and 25mg/kg of CQ plus 7 days of 0.5mg/kg/day...” PMID 40321759 ↗ Apr 2025 “csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX...” NCT02873936 ↗ “In animals, activation of the protein ataxia telangiectasia mutated (ATM) using the antimalarial drug chloroquine improves features of metabolic syndrome and decreases atherosclerosis.” NCT00455325 ↗ “The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide.” NCT00531817 ↗ “Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide.” NCT00720798 ↗ “Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)” NCT01211834 ↗ “Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US Chloroquine Phosphate tablets” NCT05232227 ↗ “Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole” NCT02366884 ↗ “DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)” NCT01256736 ↗ “single oral dose of 30 mg (base) primaquine, 600 mg (base) chloroquine, and the two drugs together” PMID 24687509 ↗ Mar 2014 Show 166 more sources
Known as	A-CQ 100	“Chloroquine, A-CQ 100” NCT00969306 ↗
Known as	Aralen	“6,000 tablets of chloroquine 150 mg (Aralen) and 6,000 identical tablets of placebo” NCT00224978 ↗
Known as	Aralen GENERIC NAME(S): Chloroquine Phosphate	“Aralen GENERIC NAME(S): Chloroquine Phosphate” NCT04341727 ↗
Known as	Chloroquine Diphosphate	“Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).” NCT04342650 ↗ 1 “Chloroquine diphosphate is an antimalarial drug that has been used for the treatment of rheumatological diseases for at the least five decades.” NCT02463331 ↗
Known as	Chloroquine phosphate	“tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base)” NCT02216123 ↗ 6 “Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg” NCT04341727 ↗ “UNIKINON (Chloroquine phosphate) 200mg tablets” NCT04344951 ↗ NCT02394197 ↗ NCT06076837 ↗ NCT04319900 ↗ NCT04286503 ↗
Known as	Chloroquine phosphate GPO	“Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).” NCT01546961 ↗
Known as	Chloroquine Sulfate	“Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days” NCT02118090 ↗ 1 “Drug: Chloroquine Sulfate” NCT04341727 ↗
Known as	Chloroquine sulphate	“Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg” NCT02698748 ↗
Known as	Meriquine	“Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg” NCT02698748 ↗
Known as	Nivaquine	“standard doses of Nivaquine® (Chloroquine) with standard doses of Rimstar® (4-drug anti-TB therapy)” NCT05443178 ↗
Known as	UNIKINON	“UNIKINON (Chloroquine phosphate) 200mg tablets” NCT04344951 ↗
Action	Inhibit	“chloroquine provides a significant inhibition on the replication of the Chikungunya virus.” NCT00391313 ↗
Modality	Small molecule	“Chloroquine is a drug of the group of 4-aminoquinolines, synthetic derivatives of quinine” NCT01980745 ↗
Route	Oral	“INTERVENTIONS: Oral chloroquine at 150 mg/d for 12 months beginning on postoperative day 5 or placebo.” PMID 16520474 ↗ Mar 2006
Target	ATM	“activation of the protein ataxia telangiectasia mutated (ATM) using the antimalarial drug chloroquine” NCT00455325 ↗